JP Morgan suggests electronics manufacturing services (EMS) firms may face valuation pressure if they fail to improve capital efficiency. As investors shift focus from pure revenue growth to Return on Capital Employed (ROCE), companies struggling with high working capital requirements or slow cash flow conversion could see their stock multiples compress.
The electronics manufacturing services (EMS) sector has experienced a significant valuation rally in recent years, largely driven by strong order book growth and optimism regarding global supply chain diversification. However, a new note from JP Morgan warns that the phase of easy valuation expansion may be ending, with investors now demanding more disciplined balance sheet management.
At the core of this shift is the concept of Return on Capital Employed, or ROCE. This metric measures how much profit a company generates for every rupee of capital invested in the business. In the EMS sector, business models are often capital-intensive. Firms must invest heavily in manufacturing facilities, machinery, and expensive electronic components before they can produce goods and generate revenue. If a company spends large sums to expand but earns low returns on that investment, the market may eventually punish its stock price.
JP Morgan highlights that many companies in this space currently face high working capital requirements. This means they often have significant cash tied up in raw materials, inventory, and trade receivables while waiting for customers to pay. When companies have high working capital needs, it limits the amount of free cash flow available. If growth begins to slow or earnings targets are missed, these capital-intensive firms are more likely to see their P/E multiples re-rated downwards.
Another layer of complexity involves the nature of modern manufacturing contracts. Many EMS players are currently investing to capture opportunities in areas like semiconductor equipment manufacturing and advanced electronics. While these segments offer high potential, they often come with long gestation periods. This means the money spent today on expansion may not translate into significant bottom-line profits for several quarters or even years. Investors have historically shown impatience with companies that report revenue growth but fail to demonstrate improving cash flow or returns on their investments.
For shareholders and potential investors, the focus is expected to move toward specific financial hygiene markers. Instead of just tracking the size of the order book or top-line revenue, it is becoming important to look at how quickly a company converts sales into actual cash and how efficiently it deploys capital to fund its expansion. Companies that can maintain strong profit margins while keeping debt levels and working capital requirements in check are better positioned to sustain their valuations in the coming quarters.